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Matthew P. Wright, John D. Shepherd, Michael J. Barnett, Stephen H. Nantel,
Heather J. Sutherland, Cynthia L. Toze, Donna E. Hogge, Thomas J. Nevill, Kevin W. Song,
Yasser R. Abou Mourad, Sujaatha Narayanan, Maryse M. Power, Clayton A. Smith,
Donna L. ForrestTyrosine kinase inhibitors (TKI) have been used to treat relapse of chronic myelogenous leukemia (CML) af-
ter allogeneic stem cell transplant (HSCT), with responses seen predominantly in chronic phase (CP) pa-
tients. This study aimed to analyze the response to TKI therapy and overall survival for patients relapsing
predominantly in advanced phase. We retrospectively reviewed 22 patients treated with imatinib (n5 20)
and/or dasatinib (n5 6) for relapsed CML after HSCT; 8 patients were in CP, and 14 patients had advanced
disease. Seven patients also received donor lymphocyte infusions. Hematologic, cytogenetic, and molecular
responses were analyzed. Nineteen patients (86%) achieved complete hematologic response (CHR), 17 pa-
tients (77%) achieved complete cytogenetic response (CCR), and 14 patients (64%) achieved complete mo-
lecular response (CMR). In advanced phase patients, 11 (79%) achieved CHR, 10 (71%) CCR, and 8 (57%)
achieved CMR. Grade 3 or 4 cytopenias occurred in 10 cases. With median follow-up of 31.5 months
from relapse, 14 (64%) patients remain alive, 13 in CMR. In multivariate analysis, the achievement of CMR
was significantly correlated with OS with an odds ratio of 20.5 (95% confidence interval 2.3-182)
P5.007. TKI therapy is capable of inducing durable molecular responses for CML relapsing after HSCT,
both in chronic and advanced phases. The achievement of CMR appears to be crucial in providing long-
term disease control for these patients.
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6/j.bbmt.2009.11.026with approximately 50% of HSCT recipients from
matched related donor remaining free of disease at 5
years [1]. However, despite its curative potential, re-
lapse can occur in approximately 25% of patients
transplanted in chronic phase (CP), and up to 37%
for those patients with advanced phase disease (accel-
erated phase [AP] and blast phase [BP]) at the time of
HSCT [2].
Until the introduction of tyrosine kinase inhibi-
tors (TKIs), first-line therapy for relapse of CML fol-
lowing transplant often consisted of reduction or
discontinuation of immunosuppression and the ad-
ministration of donor leukocyte infusions (DLIs),
harnessing the well-documented graft-versus-leuke-
mia (GVL) effect that has been observed in CML
[3]. This highly effective therapy is capable of induc-
ing responses in approximately two-thirds of patients
[4,5]. However, one-third of patients experience clin-
ically significant graft-versus-host disease (GVHD)
and myelosuppression following DLI [5], with an639
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20% [6].
The introduction of TKIs has dramatically
changed the management of patients with CML and
offers an alternative therapy to patients with persistent
or relapsing disease after HSCT. The first of the TKIs
to be developed was imatinib mesylate (IM), a small
molecule inhibitor of bcr-abl tyrosine kinase activity
[7]. Mature data on the use of IM in newly diagnosed
CP patients has shown a high rate of progression-
free survival (PFS) and complete cytogenetic remission
(CCR) [8]. Several studies have also analyzed the effect
of IM with or without DLI in patients relapsing after
HSCT for CML [9-15]. The majority of these studies
focused on patients relapsing in CP, where IM
achieved high rates of cytogenetic remission with min-
imal toxicity [11,12]. The experience using IM for
patients relapsing with advanced phase disease has
been less extensively reported. However, it is generally
thought that therapy with TKIs is less effective in this
patient population [9-11,14].
The purpose of this study was to examine out-
comes with TKI therapy and identify predictors of re-
sponse in a group of patients with CML relapsing
predominantly in advanced phase after HSCT.PATIENTS AND METHODS
Patient Characteristics
From 1982 until March 2008, 243 patients under-
went allogeneic HSCT for CML (CP 179, AP 57, BP
7) at the Vancouver General Hospital and British
Columbia Cancer Agency. Forty-five of these 243 pa-
tients relapsed. Twenty-two of the 45 relapsed patients
were treated with a TKI with or without additional
therapy (DLI and/or chemotherapy) between August
2000 and July 2008, and are the subject of this report.
Data were extracted from the Leukemia/BoneMarrow
(BM) Transplantation database and from individual
chart review. The standard monitoring practice for
patients with CML posttransplant included a BM
analysis with standard karyotyping 100 days after
transplant. In addition, institutional guidelines recom-
mended molecular analysis of bcr-abl on peripheral
blood (PB) or BM on a 3-month basis for the first 2
years, then every 6 months if complete molecular
remission (CMR) was achieved. In the event of
molecular relapse, a BM analysis and karyotype were
performed, and molecular analysis continued every 3
months or more frequently at physician discretion.
Therapeutic intervention was typically undertaken
based on cytogenetic or hematologic relapse. The
study was conducted in accordance with the Declara-
tion of Helsinki, and all patients provided informed
consent.Definition of Disease Phase, Response, and
Relapse
CML CP was defined as\10% blasts and\20%
basophils in PB or BMwithout extramedullary disease.
CML AP was defined as 10% to 20% blasts, .20%
basophils, platelet count \100 109/L unrelated to
therapy or cytogenetic clonal evolution. CML BP
was defined by.20% blasts in PB or BM, or extrame-
dullary leukemic involvement. Complete hematologic
response (CHR) was defined as normalization of PB
count and absence of all signs and symptoms of disease.
Cytogenetic responses were classified as complete if
there were no Philadelphia positive (Ph1) metaphase
cells in BM, minor (35%-95% Ph1 metaphases) or
major (1%-34% Ph1 metaphases). Hematologic re-
lapse was defined by the reappearance of a leukocytosis
in PB or BM with an abnormal differential typical of
CML with confirmation by cytogenetic analysis.
Cytogenetic relapse involved the reappearance of 1
or more Ph1 positive metaphases on cytogenetic
analysis.
Molecular Analysis
Molecular analysis was performed using RNA ex-
tracted from EDTA stabilized PB or BM. Prior to
2004 samples were analyzed by reverse transcriptase-
polymerase chain reaction (RT-PCR) followed by
agarose gel electrophoresis. Results were expressed as
positive or negative only. After 2004, patients were
monitored by real-time quantitative RT-PCR using
a 50 nuclease assay (Taqman, Applied Biosystems,
Foster City, CA). The molecular burden of disease
was established by determining the log ratio of the
bcr-abl fusion message to the bcr control message
(adapted from Hughes and Branford [16]). Log reduc-
tions were determined by comparison of the measured
value to the log value obtained at diagnosis or an aver-
aged baseline value (10.1). Major molecular response
(MMR) was defined as a 3 log reduction from baseline
(actual or average). The threshold for CMR was based
on the level below which bcr-abl transcripts were no
longer detectable (.4.5 log reduction from the aver-
aged baseline). Molecular relapse was defined as rever-
sion to a positive RT-PCR or quantitative PCR,
repeated on 2 separate occasions at least 1month apart.
Mutation analysis was performed by bidirectional
sequencing of the abl kinase domain of the bcr-abl
fusion transcript specifically, using a nested RT-PCR
technique.
Statistical Analysis
The probabilities of survival and achieving molec-
ular remission were calculated using the methods of
Kaplan and Meier [17]. The time from relapse to the
date of last contact or death was used to calculate over-
all survival (OS). The time from relapse to the most
Table 1. Patient Characteristics
Age, years
Median (range) 42 (27-59)
Sex
Male 11
Female 11
Pretransplant therapy
Imatinib 6
HU 15
Multiagent chemotherapy 6
Interval diagnosis to HSCT, months
Median (range) 8.5 (2-35.5)
Disease phase at transplant
Chronic 1 8
Chronic 2 5
Accelerated 8
Blast 1
Clonal evolution
After HSCTonly 4
Before and after HSCT 9
Type of donor
Related 15
Unrelated 7
Type of relapse at TKI initiation
Hematologic 17
Cytogenetic 5
Molecular 0
Phase at relapse
Chronic 8
Accelerated 5
Blastic (lymphoid/myeloid) 5/4
Interval from HSCT to relapse, months
Median (range) 38.5 (3-248)
Therapy after relapse
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probability of achieving CMR.
To examine potential factors influencing OS, the
following prognostic variables were analyzed: age at
HSCT, patient sex, interval from diagnosis to
HSCT, pretransplant IM therapy, disease phase at
time of transplant (chronic or advanced phase), inter-
val from HSCT to relapse, type of relapse (molecular
and cytogenetic versus hematologic), disease phase at
relapse (CP, AP, or BP), interval from relapse to TKI
therapy (\30 days versus .30 days), whether DLI
were administered, presence of acute or chronic
GVHD (aGVHD, cGVHD), donor type (related ver-
sus unrelated), achievement of CCR, achievement of
CMR, and time to CMR. Univariate analysis of cate-
goric variables and interval variables was performed
using chi-squared and t-tests analysis, respectively.
Multivariate analysis was performed using a Cox
regression model to evaluate the potential association
of those factors with OS. The same analysis was under-
taken to evaluate potential predictive factors for
achievement of CMR and included all the variables
above with the exception of CMR and time to CMR.
Variables were included in the multivariate analysis if
they had a value of P \.15 for OS and \.20 for
CMR. All P values are 2 sided.Withdrawal IS 9
HU 7
DLI 7
Imatinib 20
Dasatinib 6
Multiagent chemotherapy 3
Clinical GVHD after relapse 5
Interval relapse to TKI, days
Median (range) 25.5 (0-3298)
HU indicates hydroxyurea; HSCT, hematopoietic stem cell transplanta-
tion; IS, immunosuppression; DLI, donor leukocyte infusion; GVHD,
graft-versus-host disease; TKI, tyrosine kinase inhibitor.RESULTS
Patient Characteristics
From 1982 until March 2008, 243 patients under-
went allogeneic HSCT for CML (CP 179, AP 57, BP
7).Of these 243 patients, 45 relapsed.Treatment for re-
lapse included TKI therapy in 22 of these cases. Their
characteristics are listed in Table 1. The median age
was 42 years (range: 27 to 59 years). The stem cell
source was an HLA-matched sibling donor in 15 cases
and a matched unrelated donor in 7 cases. The condi-
tioning regimen for myeloablative (MA) sibling allo-
grafts was busulfan/cyclophosphamide (Cy; n5 12)
or Cy/total body irradiation (TBI) (n5 1). One sibling
allograft was performed with reduced intensity condi-
tioning (fludarabine/TBI), and 1 patient who had pre-
viously received a failed T cell-depleted graft from the
same sibling donor received conditioning with Cy/
antithymocyte globulin. Patients undergoing MA
matched unrelated HSCT were conditioned with Cy/
TBI (n5 6) or busulfan/Cy (n5 1). Disease status at
the time of HSCT was CP (n5 13), AP (n5 8), and
BP (n5 1). The median interval from diagnosis to
HSCTwas 8.5 months (range: 2 to 35.5). Thirteen pa-
tients received pre-HSCT therapy with either inter-
feron alpha (n5 1), IM (n5 6), or multiagent
induction chemotherapy (n5 6). In general, multi-
agent chemotherapy was utilized to induce a remission
for those patients with BP disease pre-HSCT.Theme-dian interval from HSCT to relapse was 38.5 months
(range: 3-248 months). Disease status at the time of re-
lapse was CP (n5 8), AP (n5 5 including 1 patient
with clonal evolution alone), and BP (n5 9; lymphoid
[n5 5], myeloid [n5 4]). At the time that relapse was
initially noted, 13 of these patients were in a hemato-
logic relapse, 8 in a molecular relapse, and 1 patient
was in cytogenetic relapse (Table 2). However, when
therapy with a TKI was initiated, 17 patients were in
hematologic relapse, and 5 in cytogenetic relapse (Ta-
ble 2).This reflected the delay in initiatingTKI therapy
for those patients whose initial relapse was molecular.
Cytogenetic clonal evolutionwas observed in 9 patients
both before and afterHSCT and in 4 patients at relapse
only.
Therapy Postrelapse
At the time of relapse, 11 patients were on
immunosuppressive therapy with cyclosporine and/or
Table 2. Disease Characteristics and Outcome
No.
Age (Years)/
Sex (at HSCT)
Status
(at HSCT)
Status
(at Relapse)
HSCT to
Relapse
Interval (Months)
Relapse to
TKI Interval
(Months)
Initial
Relapse
Relapse at
Start of TKI DLI TKI
Best
Response Outcome
Interval
Relapse to Last
Contact (months)
1 48 F AP CP 12 110 H H N I CMR Alive, CMR 146
2 56 M AP CP 3 25 C C Y I MiCR Died, R 83
3 41 F AP CP 3 20 M H Y I CMR Alive, CMR 67
4 38 M CP AP 65 12 M C N I CMR Alive, CMR 101
5 34 M AP BP 6.5 0.5 H H N I NR Died, R 2.5
6 49 M CP CP 120 13 M C N I CMR Alive, CMR 83
7 54 F CP CP 62 14 M C N I CMR Alive, CMR 84
8 43 F CP CP 37 12 M C N I CMR Alive, CMR 78
9 31 F CP CP 155 7.5 H H N I CMR Alive in CMR 81
10 49 M AP BP 7.5 0 H H Y I CMR Died, R 16
11 42 M CP BP 40 1 H H N I NR Died, R 7.5
12 48 M CP AP 43 1 H H Y I CMR Alive, CMR 70
13 59 M CP2 BP 2.5 1 M H N I CCR Died, R 15
14 50 F CP AP 157 0 H H Y I/D MaCR Alive, MaCR 48
15 30 M AP CP 6 0 H H Y I/D MMR Died, R 18
16 35 M AP AP 69 0.5 M H N I CMR Alive, CMR 34
17 42 F CP2 BP 45 0 H H N I CMR Alive, CMR 30
18 40 F CP2 BP 248 1 H H Y I/D MMR Died, R 15.5
19 41 F BP BP 12 0.5 M H N I/D NR Died, R 2
20 27 M CP2 BP 8 0 H H N D CMR Alive, CMR 24
21 46 F CP2 BP 3 0.5 H H N D CMR Alive, CMR 21
22 33 F AP AP 163 0 H H N I CMR Alive, CMR 5
HSCT indicates hematopoietic stem cell transplant; F, female; M, male; AP, accelerated phase; CP, chronic phase; CP2, second chronic phase; BP, blast
phase; H, hematologic; C, cytogenetic; M, molecular; DLI, donor lymphocyte infusion; Y, yes; N, no; TKI, tyrosine kinase inhibitor; I, imatinib; D, dasatinib;
CMR, complete molecular response; MiCR, minor cytogenetic response; NR, no response; CCR, complete cytogenetic response; MaCR, major cyto-
genetic response; MMR major molecular response; R, relapse.
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patients. Seven patients received DLI (CP [n5 3], AP
[n5 2], BP [n5 2]), administered either prior to
(n5 2) or concurrently with TKI therapy (n5 5).
The median number of infusions was 1 (range: 1-4),
and the total median CD3 cell dose was 1 108/kg re-
cipient body weight. Three patients underwent rein-
duction with multiagent chemotherapy (vincristine,
prednisone, and daunorubicin). Twenty patients re-
ceived IM as therapy for relapse (median daily dose
400 mg, range: 300-800). In total, 6 patients were
treated with dasatinib (CP [n5 1], AP [n5 1], BP
[n5 4]), 3 of whom had failed prior IM following re-
lapse. The median daily dasatinib dose was 140 mg
(range: 50-200). The median interval between relapse
and initiation of TKI therapy was 1 month (range:
0-110). Thirteen patients continue ongoing therapy
with IM (n5 10) or dasatinib (n5 3).Patient Outcome
In the cohort of 22 patients, 19 (86%) achieved
CHR, 17 (77%) achieved CCR, and 16 (73%)
achieved MMR including 14 (64%) who achieved
CMR. The median interval from initiation of TKI
therapy to CMR was 8 months (range: 2 to 37).
With a median follow-up of 31.5 months from re-
lapse, 14 of 22 patients (64%) remain alive, 13 of
who remain in CMR. Eight patients died because of
relapse. The 10-year OS from the date of relapsefor all 22 patients was 54% (95% CI 32%-91%)
(Figure 1).
Response in CP Relapse
Eight patients relapsed in CP. CHR was achieved
in all 8 patients. Seven patients (88%) achieved CCR
and 1 patient achieved a minor cytogenetic response.
MMR was achieved in 7 patients (88%) including 6
(75%) who achieved CMR. Six patients remain alive
in CMR, a median of 82 months (range: 67-145.5)
from the date of relapse (Figure 2).
Response in AP Relapse
Of the 14 patients relapsing in AP, 11 (79%)
achieved CHR. Ten (71%) of these reached CCR
and 1 a major cytogenetic response. MMR was
achieved in 9 patients (64%), 8 (57%) of whom
attained CMR. Eight of 14 patients (57%) with AP
relapse remain alive, 7 of who are in ongoing CMR
(Figure 2). Of the 9 patients relapsing in BP, 6 (67%)
achieved both CHR and CCR. Five patients (56%)
achieved MMR and 4 (44%) CMR. Three patients
(33%) remain alive, all in CMR at a median of
24 months (range: 21-30) from the date of relapse
(Figure 2).
Best Response by Therapy Received
Of the 15 patients treated with TKI therapy in the
absence of DLI the best response achieved was CMR
in 11, and CCR in 1 patient (Table 2). No response
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Figure 1. OS from relapse.
0.0
0.2
0.4
0.6
0.8
1.0
Months
S
u
r
v
i
v
a
l
0 20 40 60 80 100 120 140 160
AP
CP
BP
Figure 2. OS from relapse according to disease status at relapse.
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with DLI and TKI. The best response observed was
CMR in 3 cases,MMR in 2 cases (one of whom also re-
ceived combination chemotherapy), and 1 case each of
major and minor cytogenetic response.Loss of Response and Mutation Analysis
In total, 5 patients lost their best response while on
therapy (1 patient each in CMR, CCR, minor cytoge-
netic response, and 2 patients with MMR). All 5 died
from disease progression, despite therapy with dasati-
nib (n5 2) and DLI (n5 4). In the whole cohort mu-
tation testing was undertaken in only 4 patients, none
of whom obtained CMR. Two patients tested nega-
tive. Two patients had single mutations detected:
H369R and T359 G. Both failed to achieve CMR
then progressed despite TKI and DLI therapy.Toxicity
Grade 3/4 hematologic toxicity was observed in 10
patients. Nine patients experienced NCI grade 3/4
neutropenia, 7 patients grade 3/4 thrombocytopenia,
and 1 patient grade 3 anemia. In total, 6 patients re-
quired interruption or dose reduction of TKI therapy
because of cytopenia (n5 4) or intolerance (n5 2).
Five patients experienced GVHD after therapy for
relapse. In 4 patients this occurred shortly after
withdrawal of immunosuppression, and in 2 cases after
DLI.Durability of Molecular Response
Of the 14 patients who achieved CMR, 13 remain
alive inCMR amedian of 69.5months (range: 5-145.5)
from the date of relapse. In contrast, only 1 of 8 pa-
tients who failed to achieve CMR is alive. The median
duration of CMR was 27.5 months (range: 0-56). The
5-yearOS for patients that did or did not achieve CMR
was 95% (95% confidence interval [CI] 79-100) and
0% respectively, P\ .001 (Figure 3).Prognostic Factors for OS
In univariate analysis achievement of CMR
(P# .0001), relapse in CP (P5 .001), a longer interval
from relapse to initiation of TKI therapy (P5 .001),
CP disease status at HSCT (P5 .04), lack of chemo-
therapy administration pre-HSCT (p5 .02), the
achievement of CHR postrelapse (p5 .04) and the ad-
ministration of IM therapy pre-HSCT (P 5 .03) were
significant variables for OS. In multivariate analysis,
only the achievement of CMR remained significant
for OS with an odds ratio of 20.5 (95% CI 2.3-182,
P5 .007).
Prognostic Factors for CMR
The achievement of CHR (P5 .01), and a longer
interval between relapse and TKI initiation (P5 .08)
were potentially significant predictors of CMR in
univariate analysis. However, neither of these factors
remained significant in multivariate analysis.
Cessation of Imatinib
Three patients voluntarily ceased IM while in
CMR. Two of these patients experienced molecular
relapse at 23 and 11 months, respectively, but regained
CMR 3 and 9 months after recommencing IM. One
patient remains in CMR off therapy, having received
concurrent DLI early in the course of relapse.DISCUSSION
Several published reports have analyzed the effi-
cacy of IM for CML patients relapsing in CP following
allogeneic HSCT [9-13]. In general, responses have
been excellent with high rates of both hematologic
and cytogenetic remissions. Fewer reports have
focused on the response to TKI therapy for those pa-
tients relapsing with advanced disease. However, the
available literature would suggest only a minority of
these patients achieve durable cytogenetic or molecu-
lar remissions [9-11]. In our report of 22 patients
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Figure 3. OS from relapse according to the achievement of CMR.
644 Biol Blood Marrow Transplant 16:639-646, 2010M. P. Wright et al.treated with TKI therapy for relapsed CML following
HSCT, we observed a high rate of durable CMR
(59%) with minimal toxicity. These results are perhaps
somewhat surprising given the fact that 14 of these
patients had advanced disease at relapse including 9
patients in BP. Indeed, published reports examining
the efficacy of IM for the nontransplant population
have shown relatively low rates of MMR and CMR
and short PFS for patients treated in both AP (40%
at 3 years) and BP (median PFS 10 months) [18].
The majority of studies that have analyzed factors
predictive of OS following relapse were conducted
prior to the availability of TKI therapy. Factors found
to predict survival in these studies included the interval
between diagnosis and transplant [19], transplantation
in CP [19], longer interval between transplantation
and relapse [15,19], phase at relapse [15,19] andmolec-
ular rather than cytogenetic relapse [12]. Our study
also identified transplantation in CP as predictive of
survival as well as less advanced disease status at re-
lapse. Indeed, the OS for patients relapsing in CP,
AP, or BP is 75%, 100%, and 33%, respectively,
P5 .03. In addition, patients who had a longer interval
from relapse to the start of TKI therapy had a superior
outcome compared to those patients who commenced
TKI therapy #30 days from the date of relapse.
Because therapy postrelapse was only given to those
patients in our study cohort with cytogenetic or hema-
tologic relapse, the delay in therapy was limited to
those patients whose relapse was initially molecular
where continued observation was the standard
approach. As previously reported, the patients with
molecular relapse have a more favorable prognosis
[12]. We also identified the need for pre-HSCT che-
motherapy as a poor prognostic factor reflecting the
more advanced disease status associated with these pa-
tients. Finally, the achievement of CMR postrelapse
was a powerful predictor of OS, and this was the
only variable that remained independently predictive
in multivariate analysis. Fourteen of the 22 patientsin our study remain alive, and all except 1 are in
CMR. In contrast, only 1 of 8 patients who failed to
achieve CMR is still alive.
The number of patients in our study achieving
CMR postrelapse is of particular interest considering
the high percentage who relapsed in advanced phase.
Indeed, 3 of the 9 patients relapsing in BP post-
HSCT are still alive in CMR at 21, 24, and 30 months
postrelapse. In the setting of relapse after HSCT there
is little previous data on the association between CMR
and survival [4,10,12,14], and in the setting of newly
diagnosed CP patients only a small number of studies
have analyzed this relationship [20-22]. Although there
is a clear relationship between the achievement of
MMR and PFS in newly diagnosed CP patients on
IM [23], our study would appear unique in that pa-
tients who did not achieve CMR onTKI therapy expe-
rienced disease progression. This leads us to speculate
that in advanced phase relapse post-HSCT, a greater
reduction in disease burden may be necessary for
sustained disease control.
Because the attainment of CMR postrelapse ap-
pears to be crucial to long-term survival, we attempted
to identify predictors of CMR. In univarite analysis,
achieving CHR and a longer interval from relapse to
the start of TKI therapy was associated with a higher
likelihood of achieving CMR. These results are not
surprising because the attainment of CHR is a prereq-
uisite to CMR and the longer interval to the start of
TKI therapy has been previously noted in our study
to be associated with the patients in initial molecular
relapse. It was disappointing, however, that no predic-
tive factors for CMR were identified in multivariate
analysis. This likely reflects the limited statistical
power associated with such a small number of patients.
A larger study cohort is likely needed to examine this
further.
There are a number of limitations to this study,
and therefore the results should be interpreted with
caution. The use of multiple simultaneous interven-
tions (withdrawl of immunosuppression, administra-
tion of multiagent chemotherapy, DLI, and TKI
therapy) in some patients can make it difficult to deter-
mine the relative efficacy of various treatments within
individual patients. In addition, 2 different PCRmeth-
odologies were employed over the time frame of the
study, but we feel this had limited impact on the signif-
icance of the molecular responses observed. Finally,
our definition of CMR may vary from other groups
based on assay methodology and sensitvity and should
not be equated with disease eradication. [24]
In conclusion, we have demonstrated encouraging
responses to TKI therapy in AP relapse of CML after
HSCT. TKI therapy may be considered first line in
this setting, particularly in late-relapsing patients, IM
naı¨ve patients, and in the absence of resistant muta-
tions. It has previously been shown that molecular
Biol Blood Marrow Transplant 16:639-646, 2010 645Response to Tyrosine Kinase Inhibitor Therapymonitoring after transplant may predict patients at
higher risk of relapse [25-28], and guidelines for the
timing and interpretation of molecular monitoring
post HSCT have been proposed [25,26]. Regular
monitoring of molecular response to therapy may be
particularly important after relapse, as we have found
that patients not achieving CMR appear to have
a high risk of disease progression. There currently
are no recommendations for alteration of therapy
based on failure to achieve CMR, either during initial
therapy [29] or in the setting of relapse. Although DLI
did not appear to have an impact on survival in our pa-
tients, other studies have found it may act synergisti-
cally with TKI therapy [10,14]. Patients who fail to
achieve CMR on TKI therapy alone should therefore
be considered candidates for combination therapy
with both TKI and DLI.ACKNOWLEDGMENTS
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